A follow-up study can associate a negative drug test with improved heart function without establishing continuous abstinence throughout the interval. That measurement issue is central to a historical methamphetamine-associated heart-failure cohort reported by Bhatia and colleagues.
How was cessation classified?
The retrospective study separated reduced ejection fraction, defined as below 50%, from preserved ejection fraction, defined as at least 50%. Baseline methamphetamine exposure required positive urine toxicology. Cessation meant a negative urine test nearest the end of the initial 12-month follow-up, rather than continuous verified nonuse.
There were 28 methamphetamine-associated reduced-EF patients: 14 classified as continuing use and 14 as cessation. A separate preserved-EF group contained 28 patients, with 15 continuing and 13 classified as cessation. Echocardiographic follow-up extended to one year; later clinical outcomes covered months 12–24.
What improved, and in whom?
In the reduced-EF cessation group, mean absolute EF change was +10.6 percentage points, SD 13.1, with p = 0.009 for change from baseline. The continuing group changed by −1.7 points, SD 12.5, p = 0.616. These are changes in the proportion pumped, not relative percentage increases or measurements of fibrosis disappearing.
Later heart-failure admissions were lower in the cessation group: median 0 per year, interquartile range 0–1, versus 2, interquartile range 1–3, with continuing use; p = 0.039. That comparison had 12 patients per methamphetamine group, fewer than the 14 per group in the EF analysis.
Why does the changing denominator matter?
The pumping and admission results concern different follow-up measurements and available samples. Reporting the initial 28 as though every patient contributed equally to every later outcome hides attrition. A claim about admissions should retain the relevant clinical-outcome denominator.
The study also selected patients with serial echocardiograms. People who died or were lost before providing that sequence were not represented in the same way. Observed improvement among retained patients cannot automatically become a prognosis for all newly presenting patients.
Did preserved-EF patients show the same pattern?
No corresponding significant improvement in echocardiographic measures and clinical outcomes was demonstrated after cessation in the preserved-EF group. Preserved and reduced EF should therefore remain separate evidence categories. Combining them into a single statement that methamphetamine-associated heart failure reversed would omit an important null finding.
Can the urine result establish why improvement occurred?
A negative test near one year cannot reconstruct every exposure between visits. The authors expressly identified this limitation and documented recurrent positive tests during later follow-up in some patients initially classified as cessation.
Medical treatment, medication adherence, access to care and baseline illness may also differ between observational groups. Prescription documentation did not verify actual medication use. The authors’ adjusted clinical analyses were exploratory, with small samples limiting their interpretation.
What is the defensible conclusion?
This cohort documented an encouraging association in selected reduced-EF patients, using a specific toxicological definition of cessation. It did not measure a universal probability of recovery, demonstrate continuous abstinence, or isolate cessation from all accompanying changes. For a scientific opinion, preserve the exposure definition, cardiac phenotype, follow-up window and denominator before discussing reversibility.
Source
Bhatia and colleagues. Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation. Heart. 2021;107(9):741–747. Published online October 5, 2020. DOI: 10.1136/heartjnl-2020-317635. Full text; bibliographic record.